A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Interventions: DRUG: Giredestrant|DRUG: Giredestrant-matched Placebo|DRUG: Letrozole|DRUG: Letrozole-matched Placebo|DRUG: Palbociclib|DRUG: LHRH Agonist
Sponsor: Hoffmann-La Roche